ArticleScientific reports2026
Extracellular vesicle delivery of Myricetin suppresses ovarian cancer through mitochondrial dynamics by downregulating the ECM1/NF-κB/TGFβ signaling pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is classified as a female malignancy commonly known as a silent killer with no early detection symptoms. Extracellular matrix protein 1 (ECM1) is associated with the Epithelial-mesenchymal transition (EMT) and metastasis process in different cancers. However, the function of ECM1 in mitochondrial dynamics in ovarian cancer is yet to be determined. Myricetin (MYR) is a flavonoid with medicinal impact on cell proliferation, inflammation, and metastasis. The role of MYR in influencing ECM1 levels to counter ovarian cancer remains unexplored. Chinese hamster ovary (CHO) cells are known to produce protein-based biotherapeutics for various diseases; here, CHO cell-derived extracellular vesicles (CE) can serve as a delivery vehicle of MYR in translational medicine. The current research focused on developing a Myricetin-loaded CHO cell-derived extracellular vesicles (CE + MYR) formulation to facilitate efficient delivery of MYR to target OVCAR3 tumor cells, thereby affecting the ECM1 signaling mechanism. An investigation was carried out to assess the cytotoxic effects of CE + MYR on ovarian cells using an MTT assay to compare the viability of normal CHO cells and the tumor OVCAR3 cells. A decrease in the viability of OVCAR3 cells was observed at IC50 42 µM with MYR treatment and at 30 µM with CE + MYR treatment, indicating the efficiency of CE in delivering MYR; nonetheless, CHO cells remained unaffected at these concentrations. There was an alteration in cell morphology, nuclear fragmentation, decreased migration, and lower mitochondrial membrane potential in the OVCAR3 cells, whereas the CHO cells remained unaffected. There were more apoptotic cells in tumor-treated cells. CE + MYR reduces the expression of ECM1, NF-κB, and TGFβ, whereas the expression of PTEN, p53, and caspases was enhanced. Myricetin inhibited mitochondrial fission (DRP1 and FIS1) and favored mitochondrial fusion (MFN1 and MFN2). Encapsulating myricetin in CE enhanced antitumor efficacy against ovarian cancer by suppressing proliferation and mitochondrial fission, thereby promoting mitochondrial fusion and apoptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.